Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management During Immunotherapy

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Jun 28

PMID 37371863

Authors

Areti Strati

Panagiota Economopoulou

Evi Lianidou

Amanda Psyrri

Affiliations

Soon will be listed here.

Abstract

The approval of monoclonal antibodies against programmed death-ligand 1 (PD-L1) and programmed cell death protein (PD1) has changed the landscape of cancer treatment. To date, many immune checkpoint inhibitors (ICIs) have been approved by the FDA for the treatment of metastatic cancer as well as locally recurrent advanced cancer. However, immune-related adverse events (irAEs) of ICIs highlight the need for biomarker analysis with strong predictive value. Liquid biopsy is an important tool for clinical oncologists to monitor cancer patients and administer or change appropriate therapy. CTCs frequently express PD-L1, and this constitutes a clinically useful and non-invasive method to assess PD-L1 status in real-time. This review summarizes all the latest findings about the clinical significance of CTC for the management of cancer patients during the administration of immunotherapy and mainly focuses on the assessment of PD-L1 expression in CTCs.

Citing Articles

Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.

Kotsifaki A, Maroulaki S, Armakolas A Int J Mol Sci. 2024; 25(9).

PMID: 38732051 PMC: 11084220. DOI: 10.3390/ijms25094832.

Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.

Roumeliotou A, Strati A, Chamchougia F, Xagara A, Tserpeli V, Smilkou S Cells. 2024; 13(9.

PMID: 38727318 PMC: 11083423. DOI: 10.3390/cells13090782.

References

Hong X, Sullivan R, Kalinich M, Kwan T, Giobbie-Hurder A, Pan S . Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018; 115(10):2467-2472. PMC: 5877960. DOI: 10.1073/pnas.1719264115. View

Tan Z, Yue C, Ji S, Zhao C, Jia R, Zhang Y . Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. Oncologist. 2021; 26(12):e2227-e2238. PMC: 8649012. DOI: 10.1002/onco.13981. View

Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S . Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Cancers (Basel). 2019; 11(6). PMC: 6627043. DOI: 10.3390/cancers11060835. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Economopoulou P, Kladi-Skandali A, Strati A, Koytsodontis G, Kirodimos E, Giotakis E . Prognostic impact of indoleamine 2,3-dioxygenase 1 mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. ESMO Open. 2020; 5(3):e000646. PMC: 7232623. DOI: 10.1136/esmoopen-2019-000646. View

Zhou Q, Liu X, Li J, Tong B, Xu Y, Chen M . Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thorac Cancer. 2023; 14(5):470-478. PMC: 9925337. DOI: 10.1111/1759-7714.14767. View

Mondelo-Macia P, Garcia-Gonzalez J, Abalo A, Mosquera-Presedo M, Aguin S, Mateos M . Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients. Transl Lung Cancer Res. 2022; 11(10):1995-2009. PMC: 9641037. DOI: 10.21037/tlcr-22-273. View

Kolostova K, Pospisilova E, Matkowski R, Szelachowska J, Bobek V . Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells. Cancer Immunol Immunother. 2022; 71(12):2901-2911. PMC: 10992224. DOI: 10.1007/s00262-022-03189-2. View

10.

Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L . Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015; 9(9):1773-82. PMC: 5528721. DOI: 10.1016/j.molonc.2015.05.009. View

11.

Mondelo-Macia P, Garcia-Gonzalez J, Leon-Mateos L, Anido U, Aguin S, Abdulkader I . Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab. Mol Oncol. 2021; 15(11):2923-2940. PMC: 8564635. DOI: 10.1002/1878-0261.13094. View

12.

Ralli M, Botticelli A, Visconti I, Angeletti D, Fiore M, Marchetti P . Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res. 2020; 2020:9235638. PMC: 7338969. DOI: 10.1155/2020/9235638. View

13.

Alix-Panabieres C, Pantel K . Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11(4):858-873. DOI: 10.1158/2159-8290.CD-20-1311. View

14.

Mego M, Gao H, Cohen E, Anfossi S, Giordano A, Tin S . Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2016; 8(22):35656-35668. PMC: 5482606. DOI: 10.18632/oncotarget.10290. View

15.

Shibata H, Saito S, Uppaluri R . Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. Front Oncol. 2021; 11:727433. PMC: 8451593. DOI: 10.3389/fonc.2021.727433. View

16.

Liang S, Xu K, Niu L, Wang X, Liang Y, Zhang M . Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. Onco Targets Ther. 2017; 10:4273-4281. PMC: 5584889. DOI: 10.2147/OTT.S139986. View

17.

Spiliotaki M, Neophytou C, Vogazianos P, Stylianou I, Gregoriou G, Constantinou A . Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. Mol Oncol. 2022; 17(5):792-809. PMC: 10158784. DOI: 10.1002/1878-0261.13317. View

18.

Economopoulou P, Koutsodontis G, Strati A, Kirodimos E, Giotakis E, Maragoudakis P . Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). Oral Oncol. 2019; 94:93-100. DOI: 10.1016/j.oraloncology.2019.05.019. View

19.

Darga E, Dolce E, Fang F, Kidwell K, Gersch C, Kregel S . PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One. 2021; 16(11):e0260124. PMC: 8592410. DOI: 10.1371/journal.pone.0260124. View

20.

Ikeda M, Koh Y, Teraoka S, Sato K, Oyanagi J, Hayata A . Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers (Basel). 2021; 13(10). PMC: 8150706. DOI: 10.3390/cancers13102290. View